Adam Logal - Opko Health CFO
| OPK Stock | 675.00 23.30 3.58% |
CFO
Mr. Adam E. Logal serves as Senior Vice President, Chief Financial Officer of the Company. Mr. Logal has served as OPKOs Senior Vice President and Chief Financial Officer since March 2014, Vice President of Finance, Chief Accounting Officer and Treasurer from July 2012 until March 2014, and Director of Finance, Chief Accounting Officer and Treasurer from March 2007 until July 2012. He currently serves as chairman of the board of directors of Xenetics Biosciences, Inc., a clinicalstage biopharmaceutical company focused on discovery, research and development of nextgeneration biologic drugs and novel orphan oncology therapeutics. He previously served on the board of directors of VBI Vaccines, Inc. until 2018. From 2002 to 2007, Mr. Logal served in senior management of Nabi Biopharmaceuticals, a publicly traded, biopharmaceutical company engaged in the development and commercialization of proprietary products. Mr. Logal held various positions of increasing responsibility at Nabi Biopharmaceuticals, last serving as Senior Director of Accounting and Reporting. since 2014.
| Age | 45 |
| Tenure | 11 years |
| Phone | 305 575 4100 |
| Web | https://www.opko.com |
Adam Logal Latest Insider Activity
Tracking and analyzing the buying and selling activities of Adam Logal against Opko Health stock is an integral part of due diligence when investing in Opko Health. Adam Logal insider activity provides valuable insight into whether Opko Health is net buyers or sellers over its current business cycle. Note, Opko Health insiders must abide by specific rules, including filing SEC forms every time they buy or sell Opko Health'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Adam Logal over six months ago Acquisition by Adam Logal of 437500 shares of Opko Health subject to Rule 16b-3 | ||
Adam Logal over a year ago Acquisition by Adam Logal of 6250 shares of Xenetic Biosciences at 2.95 subject to Rule 16b-3 | ||
Adam Logal over a year ago Acquisition by Adam Logal of 6250 shares of Xenetic Biosciences subject to Rule 16b-3 |
Opko Health Management Efficiency
The company has return on total asset (ROA) of (0.0659) % which means that it has lost $0.0659 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1867) %, meaning that it generated substantial loss on money invested by shareholders. Opko Health's management efficiency ratios could be used to measure how well Opko Health manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | CFO Age | ||
| Joseph Gaspar | Elbit Systems | 74 | |
| Beth Gaspich | Nice | 57 | |
| Chaime Orlev | Kamada | 53 | |
Management Performance
| Return On Equity | -0.19 | |||
| Return On Asset | -0.0659 |
Opko Health Leadership Team
Elected by the shareholders, the Opko Health's board of directors comprises two types of representatives: Opko Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Opko. The board's role is to monitor Opko Health's management team and ensure that shareholders' interests are well served. Opko Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Opko Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Arie Gutman, Pres API | ||
| James DeMarco, VP Sales | ||
| Adam Logal, CFO, Chief Accounting Officer, Sr. VP and Treasurer | ||
| Phillip Frost, Chairman of the Board, CEO | ||
| Akhtar Ashfaq, Senior Vice President - Clinical Research and Development of OPKO Health's Renal Division | ||
| Elias MD, Pres Chairman | ||
| JD Esq, Chief Laboratories | ||
| MBA MBA, Vice Officer | ||
| Jon MD, Advisor |
Opko Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Opko Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.19 | |||
| Return On Asset | -0.0659 | |||
| Profit Margin | (0.26) % | |||
| Operating Margin | (0.20) % | |||
| Current Valuation | 3.9 B | |||
| Shares Outstanding | 772.69 M | |||
| Shares Owned By Insiders | 45.87 % | |||
| Shares Owned By Institutions | 24.36 % | |||
| Price To Book | 0.63 X | |||
| Price To Sales | 2.78 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Opko Stock
When determining whether Opko Health is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Opko Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Opko Health Stock. Highlighted below are key reports to facilitate an investment decision about Opko Health Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Opko Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Opko Stock refer to our How to Trade Opko Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.